ArticleGene therapy2001
Efficient in vivo gene transfer by PCR amplified fragment with reduced inflammatory activity.
Article in Gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 65 citations in OpenAlex.
- Article
- A novel micro-linear vector for in vitro and in vivo gene delivery and its application for EBV positive tumors.PloS one · 2012Article
- Dysopsonin activity of serum DNA-binding proteins favorable for gene delivery.The Journal of pharmacology and experimental therapeutics · 2010Article
- Lipid-based systemic delivery of siRNA.Advanced drug delivery reviews · 2009Review
- Cloning-free regulated monitoring of reporter and gene expression.BMC molecular biology · 2009Article
- Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation.The AAPS journal · 2009Review
- Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects.Gene therapy · 2005Review
- Hydroporation as the mechanism of hydrodynamic delivery.Gene therapy · 2004Article
- Thermosensitive hydrogel as a Tgf-beta1 gene delivery vehicle enhances diabetic wound healing.Pharmaceutical research · 2003Article
- Gene therapy of hepatocarcinoma: a long way from the concept to the therapeutical impact.Cancer gene therapy · 2003Review
- Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia.Gene therapy · 2003Review
- Gene therapy progress and prospects: nonviral vectors.Gene therapy · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
There are many problems associated with plasmid DNA that may limit its use in systemic gene transfer. These problems could be solved by the use of synthetic genes. As a model to test the feasibility of using synthetic genes for gene therapy, we PCR-amplified a fragment containing the CMV promoter, the luciferase gene and a polyadenylation signal. The in vivo expression efficiency of the PCR fragment was determined by using two different methods, a hydrodynamics-based gene transfer of naked DNA to the liver and LPD (a lipid-based vector) mediated gene transfer to the lung. Our results show that linear fragments are at least as active as plasmid DNA following systemic delivery by LPD. However, PCR fragments are much less inflammatory than plasmid DNA as shown by a three-fold reduction in serum levels of both TNF-alpha and IL-12. Our results also showed that PCR fragments are highly efficient in liver gene transfer following systemic administration in a large volume. Thus, these results support the idea of using synthetic genes for gene therapy. Since gene sequence can be easily obtained as a PCR fragment, our results also imply that it may provide a useful and convenient method for determining the physiologic function of a putative gene in intact animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.